AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What's New in Rosacea?

Description

In this update about rosacea, Linda Steingold from Henry Ford Health emphasizes the importance of recognizing comorbidities associated with the condition, such as neurologic and cardiovascular diseases. Traditional subtype classification has shifted towards a phenotype-based approach, diagnosing rosacea primarily through fixed central facial erythema and phymatus changes. Current treatments include topical and oral anti-inflammatory agents, with recent studies showing that ivermectin cream is more effective than metronidazole for inducing long-term remission. Topical minocycline foam shows promising results in clearing moderate to severe rosacea, while encapsulated benzoyl peroxide demonstrates efficacy with better tolerability compared to over-the-counter versions. The combination of topical ivermectin and alpha-adrenergic agonists like brimonidine has shown synergistic effects, significantly reducing inflammatory lesions. Additionally, long-term use of oxymetazoline may enhance treatment outcomes, potentially modifying the disease course. Finally, paroxetine has been assessed as a treatment for background erythema, with positive results. The landscape for rosacea treatments is improving, with ongoing research promising brighter outcomes for patients.

View more

Conclusions

  • Rosacea is associated with an increased risk of various comorbidities, particularly cardiovascular diseases.
  • The classification of rosacea has transitioned from a subtype approach to a phenotype-based diagnosis.
  • Ivermectin 1% cream shows superior efficacy to metronidazole 0.75% in treating papulopustular rosacea and provides longer-lasting remission.
  • Achieving complete clearance of rosacea leads to a significantly longer time before relapse compared to achieving almost clear skin.
  • Tetracyclines have non-antibiotic anti-inflammatory properties that contribute to the management of rosacea.
  • Topical minocycline foam (1.5%) has been shown to be effective for treating moderate to severe papulopustular rosacea with favorable safety profiles.
  • Microencapsulated benzoyl peroxide is effective for rosacea while minimizing irritation, demonstrating improved tolerability compared to traditional formulations.
  • Combining ivermectin and brimonidine can enhance treatment outcomes in rosacea patients.
  • Oxymetazoline may modify disease progression over time by reducing persistent erythema in rosacea patients.
  • Paroxetine has potential as a treatment option for refractory erythema in rosacea, addressing vascular dysregulation.
  • Woo YR, et al. Int J Mol Sci. 2020;21(22):8427.
  • Scharschmidt TC, et al. Arch Dermatol. 2011;147(1):123-126.
  • Pagan AD, Jung S, Caldas S, Ungar J, Gulati N, Ungar B. Cross-Sectional Study of Psoriasis, Atopic Dermatitis, Rosacea, and Alopecia Areata Suggests Association With Cardiovascular Diseases. J Drugs Dermatol. 2023 Jun 1;22(6):576-581.
  • Wilkin et al. J Am Acad Dermatol. 2002;
  • Huynh. Am Health Drug Benefits. 2013;
  • Del Rosso. J Clin Aesthet Dermatol. 2012.
  • Tan J, et al. Br J Dermatol. 2017;176(2):431-438.
  • Gallo JR, et al. J Am Acad Dermatol. 2017;78(1):148-155.
  • Del Rosso JQ, et al. Cutis. 2013;92(5):234-240.
  • Van Zuuren EJ, et al. Br J Dermatol. 2019;181(1):65-79.
  • Taieb A, et al. Br J Dermatol. 2014; DOI: 10.1111/bjd.13408.
  • Gold LS, Del Rosso JQ, Kircik L, Bhatia ND, Hooper D, Nahm WK, Stuart I. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020 May;82(5):1166-1173.
  • Tsianakas A, et al. Minocycline Extended-Release Comparison with Doxycycline for the Treatment of Rosacea: A Randomized, Head-to-Head, Clinical Trial. The Journal of clinical and aesthetic dermatology vol. 14,12 (2021): 16-23.
  • Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. doi: 10.1016/j.jaad.2018.01.027.
  • Wang B, Huang Y, Tang Y, et al. Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial. J Am Acad Dermatol. 2023 Jun;88(6):1300-1307.